Medicamen Biotech: FY26 Results; Final Dividend of ₹1.00 Approved

Medicamen Biotech Ltd. announced audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board approved a final dividend of ₹1.00 per equity share of face value ₹10.00, subject to shareholder approval. They also approved the appointment of M/s SPB & Co as cost auditor and M/s Cheena & Associates as internal auditor for FY 2026-27. The audit reports issued by M/s Rai Qimat & Associates on the financial statements contained unmodified opinions. The board meeting concluded on May 27, 2026.